Inhibition of efflux pumps by FDA-approved drugs oxiconazole and sertaconazole restores antibiotic susceptibility in multidrug-resistant S. aureus

This study found that sertaconazole and oxiconazole, two FDA-approved antifungal drugs, can boost the effectiveness of certain antibiotics against drug-resistant Staphylococcus aureus by inhibiting efflux pumps, which bacteria use to remove antibiotics from their cells. The research was conducted in vitro and using a mouse skin infection model. Further research is needed to confirm these findings in humans and explore broader applicability.

None identified.

This is a well-conducted study with a clear rationale, robust methodology, and promising results. The in vitro and in vivo experiments convincingly demonstrate the synergistic effect of sertaconazole and oxiconazole with existing antibiotics. The study also investigates the mechanism of action, providing a plausible explanation for the observed effects. The limitations regarding the number of strains tested and the lack of human studies are acknowledged and do not detract significantly from the overall quality of the research.